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Abstract Introduction: Efficacy of renin-angiotensin-aldosterone system (RAAS)
blockade using angiotensin-converting enzyme inhibitors (ACEi) in dogs with precli-
nical myxomatous mitral valve disease (MMVD) is controversial.
Hypothesis: Administration of spironolactone (2e4 mg q 24 h) and benazepril
(0.25e0.5 mg q 24 h) in dogs with preclinical MMVD, not receiving any other cardiac
medications, delays the onset of heart failure (HF) and cardiac-related death.
Moreover, it reduces the progression of the disease as indicated by echocardio-
graphic parameters and level of cardiac biomarkers N-terminal pro brain natriuretic
peptide (NT-proBNP) and cardiac troponin I (cTnI).
Animals: 184 dogs with pre-clinical MMVD and left atrium-to-aortic root ratio
(LA:Ao) 1.6 and normalized left ventricular end-diastolic diameter (LVEDDn)
1.7.
Methods: This is a prospective, randomized, multicenter, single-blinded, placebo-
controlled study. Primary outcome variable was time-to-onset of first occurrence
of HF or cardiac death. Secondary end points included effect of treatment on pro-
gression of the disease based on echocardiographic and radiographic parameters, as
well as variations of NT-proBNP and cTnI concentrations.
Results: The median time to primary end point was 902 days (95% confidence
interval (CI) 682-not available) for the treatment group and 1139 days (95% CI
732-NA) for the control group (p ¼ 0.45). Vertebral heart score (p ¼ 0.05), LA:Ao
(p < 0.001), LVEDDn (p < 0.001), trans-mitral E peak velocity (p ¼ 0.011), and
NT-proBNP (p ¼ 0.037) were lower at the end of study in the treatment group.
Conclusions: This study failed in demonstrating that combined administration of
spironolactone and benazepril delays onset of HF in dogs with preclinical MMVD.
However, such treatment induces beneficial effects on cardiac remodeling and
these results could be of clinical relevance.
ª 2020 The Authors. Published by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Myxomatous mitral valve disease (MMVD) is the
most common cardiovascular disease observed in
dogs and the most frequent cause of heart failure
(HF) in this species [1,2]. The disease has a rela-
tively long preclinical period defined as stage B1,
characterized by the absence of radiographic or
echocardiographic evidence of cardiac remodel-
ing, and stage B2, when affected dogs present with
evidence of left atrial and/or left ventricular
enlargement [3,4]. Over the years, various medical
interventions to delay the onset of HF in asymp-
tomatic dogs affected by MMVD and cardiac
remodeling have been evaluated by prospective,
placebo-controlled, double-blinded multicenter
clinical trials. In a large study involving 360 dogs
with MMVD stage B2, the administration of pimo-
bendan, a calcium sensitizer and
phosphodiesterase-3 inhibitor, resulted in pro-
longation of the preclinical stage by approximately
15 months [5]. Conversely, two studies evaluating
the effectiveness of enalapril, an angiotensin-
converting enzyme inhibitor (ACEi), have failed
to provide clear evidence of delaying the onset of
HF, despite the clinical efficacy demonstrated in
dogs with HF [6,7]. Such therapeutic failure could
be attributed, at least in part, to an inefficient
suppression of aldosterone secretion through a
mechanism known as aldosterone breakthrough
(ABT), especially when an ACEi is given for a rel-
atively long time, with circulating aldosterone
concentrations increasing above pretreatment
levels [8]. Indeed, high levels of circulating
aldosterone can contribute to the progression of
heart disease in humans by promoting cardiac fib-
rosis and hypertrophy, as well as enhancing
inflammatory cell function [9e11]. It appears that
ABT is a common occurrence also in approximately
30% of dogs with preclinical MMVD receiving an
ACEi [12]. Therefore, the addition of the miner-
alocorticoid receptor antagonist spironolactone to
an ACEi could potentially delay the progression of
heart disease in dogs with preclinical MMVD, by
providing a more effective suppression of the
renin-angiotensin-aldosterone system (RAAS).
Based on these considerations, we hypothesized
that the combined chronic administration of spi-
ronolactone and benazepril in dogs affected by
MMVD with cardiac remodeling (stage B2), not
receiving any other cardiac medications, can delay
the onset of HF compared with similar dogs
receiving placebo. We also hypothesized that
chronic treatment with spironolactone and bena-
zepril reduces the progression of the disease as
indicated by specific imaging variables and level of
cardiac biomarkers N-terminal pro brain natriu-
retic peptide (NT-proBNP) and cardiac troponin I
(cTnI).
Animals, material, and methods
Study design
The “DELay of Appearance of sYmptoms of canine
degenerative mitral valve disease treated with
spironolactone and benazepril” (DELAY) study was
a prospective, multicenter, single-blinded,
randomized, placebo-controlled study. The study
protocol was designed by an independent group of
cardiologists (M.B., C.B., D.C., F.M., L.F., G.D.,
M.P., R.A.S., the Scientific Committee for the
DELAY study [SCDS]) in conjunction with the
sponsor. The study was approved by the Italian,
Dutch, and United Kingdom agencies for veterinary
drugs. The study was approved by an ethical
review committee at each site where this was
required. The contract between the sponsor and
the lead investigator (M.B.) stipulated that the
latter would have full access to all results and the
right to independently publish the study regardless
of the outcome.
Abbreviations
ABT Aldosterone breakthrough
ACEi Angiotensin-converting enzyme
inhibitor
CI Confidence interval
cTnI Cardiac troponin I
DELAY DELay of Appearance of sYmptoms of
canine degenerative mitral valve
disease treated with spironolactone
and benazepril
E peak Early transmitral peak velocity
HF Heart failure
ITT Intention-to-treat population
LA:Ao Left atrium-to-aortic root ratio
LVEDDn Normalized left ventricular end-
diastolic diameter
MMVD Myxomatous mitral valve disease
NA Not available
NT-proBNP N-terminal pro brain natriuretic
peptide
PP Per protocol population
RAAS Renin-angiotensin-aldosterone system
SCDS Scientific committee for the DELAY
study
U A:C Urine aldosterone-to-creatinine ratio
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Dogs
Privately owned dogs were enrolled in twenty-one
centers in Europe (sixteen in Italy, one in the Neth-
erlands, and four in the United Kingdom) between
November 2010 and June 2014 (Italy), December
2013 and August 2014 (the Netherlands), and April
2014 and September 2014 (the United Kingdom).
The follow-up phase was terminated on 31 January
2018 in Italy, 30 September 2017 in the Netherlands,
and 31 March 2018 in the United Kingdom. All
authors but four (M.B., K.L., E.G., and C.G.P.) were
also investigators recruiting cases.
The enrollment criteria were as follows: Dogs
were eligible for participation in the study only if
the owner had given informed written consent. To
be eligible for inclusion, a dog had to be between 4
and 14 years of age, have a body weight 2.5 kg
and 20 kg, have a left apical systolic murmur, and
had to be in American College of Veterinary
Internal Medicine (ACVIM), stage B2 of MMVD [3].
For this study, a B2 dog was defined by the pres-
ence of echocardiographic evidence of MMVD with
cardiac remodeling, absence of current or pre-
viously reported clinical signs attributable to HF,
and absence of pulmonary edema on thoracic
radiographs. The diagnosis of MMVD was based on
the presence of mitral valve leaflets thickening
and/or mitral valve prolapse and the presence of
mitral regurgitation on color Doppler study. In this
study, cardiac remodeling was defined by a left
atrium-to-aortic root ratio (LA:Ao)  1.6 [13] and a
normalized left ventricular end-diastolic diameter
(LVEDDn)  1.7 [14].
The exclusion criteria were as follows: Dogs were
excluded from the study if they had cardiovascular
disease other than MMVD (including congenital
diseases), presence of atrial fibrillation docu-
mented by electrocardiographic recording, past
treatment with cardiovascular drugs lasting more
than two weeks or during the last two weeks before
inclusion, systemic hypertension (defined as a sys-
tolic pressure over 180 mmHg on five repeated
measurements), pulmonary hypertension (diag-
nosed by the presence of a tricuspid regurgitation
velocity > 3 m/s assessed by spectral Doppler
study), and clinically relevant systemic disease.
Randomization and allocation
Dogs were allocated to treatment groups by ran-
domization. A statistician was responsible for ran-
domizing treatments for dogs enrolled in the study.ac
A computer-generated randomizationad table was
provided by the statistician to each clinic. Dogs were
randomized based on the order of presentation at
each site. At the time of enrollment, each dog was
given a unique identification number and was
assigned to a treatment code based on the random-
ization table for that site. Each investigator was
assigned 24 consecutive study numbers. The max-
imum number of cases enrolled at any single center
was 14.
Blinding
Each clinical investigator was blinded to the
treatment codes and treatment assignment of
subjects. Treatment was provided by an appointed
dispenser who was aware of the treatment codes
but kept this information strictly confidential and
did not participate in or influenced the clinical
evaluations. Although the study was designed to be
single-blinded, interventions to maintain the
owner blinded of treatment were attempted.
These included the modification of the original
packaging of the treatment drugs with dedicated
blister wallets. Forms and other documents rela-
ted to treatment identity were stored in a secure
location at each site to maintain blinding. Owners
and site personnel were given guidance to prevent
them from disclosing accidentally information that
would unblind the investigator. Drugs were dis-
pensed in sealed cardboard boxes to prevent
inadvertent disclosure of the treatment group of
investigators.
Treatment groups
Spironolactone (Prilactone 10 mg and 40 mg
tablets) and benazepril chlorhydrate (Fortekor
2.5 and 5 mg tablets) were administered PO at the
target dose of 2e4 mg/kg q 24 h for spironolactone
and 0.25e0.5 mg/kg q 24 h for benazepril. The
calculated dose was adjusted to a suitable number
of tablets. Placebo (10 mg and 40 mg tablets) was
administered PO q 24 h, and all dogs received two
placebo tablets q 24 h to match the treatment
administration. Assessment of compliance was
ensured by asking the owner to return empty,
partially used, or unused blisters of tablets every
three months. At each visit, the dispenser counted
the remaining tablets and provided the correct
number of tablets needed for three months. Lack
of administration, noticed by the dispenser or
reported by the owner at each visit for more than
ac Ceva Sante´ Animale Biostatistic Department. ad PLAN procedure in SAS, SAS Institute, Cary NC.
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ten consecutive days or more than 20% of the
follow-up duration in total, was considered as a
major deviation leading to removal from the
analysis of data in the per protocol (PP)
population.
Population analyzed
All dogs that were randomized and received at
least one dose of the treatment or the placebo
were included in the intention-to-treat (ITT)
population. Only dogs for which the protocol was
strictly respected could be included in the PP
population. Dogs remained in the study until one
of the following occurred: the dog reached the
primary end point, the dog was censored from
the primary end point analysis owing to occur-
rence of an event that precluded continuation of
the study or the eighth follow-up visit was
completed.
Concomitant treatment
Any concomitant treatment was under the
responsibility of the investigator and had to be
described in detail (name, concentration, daily
dose, route of administration, justification) on the
case report form. Forbidden concomitant treat-
ments included any cardiovascular treatment
other than the study drugs or any treatment that
could interact with the evaluation of the tested
product. In case of administration of any forbidden
treatment, the dog was censored from the PP
analysis. An exception for forbidden drug was the
short-term administration of any cardiovascular
drug for a period of less than seven days. Other
concomitant medications, therapies or vaccines
were allowed as long as they were considered not
to be interacting with the evaluation of the tested
product after approval by the lead investigator
(M.B.). The use of such concomitant treatment had
to be reserved only to guarantee the best standard
of care of enrolled dogs.
Visit schedule
Eight mandatory visits were scheduled from day 0
to month 42 every 6 months. Additional visits were
allowed for medical concerns. Table 1 summarizes
the scheduled visits and diagnostics tests per-
formed at each visit.
Clinical evaluation
At the inclusion, dogs’ characteristics (breed, age,
sex, body weight, and body condition score) were
recorded. Clinical history and physical findings
were documented at each visit.
Thoracic radiographs
Thoracic radiographs were performed at each
scheduled visit. Cardiac size was assessed by the
vertebral heart scale method [15]. Radiographs
were first evaluated by the investigator and, in
case of detection of pulmonary edema, this had to
be confirmed by the lead investigator (M.B.) within
7 days. In case of discrepancy between the two
evaluators (investigator and M.B.), a third opinion
from a certified boarded radiologist, blinded to
dog clinical status, had to be requested.
Table 1 Scheduled visit for each dog and diagnostic tests performed at each visit.
Visit No. V1 V2 V3 V4 V5 V6 V7 V8a
Day/month D0 M6 M12 M18 M24 M30 M36 M42
Physical examination O O O O O O O O
Serum CRT O
ECG O
Thoracic radiography O O O O O O O O
Echocardiography O O O O O
Systolic blood pressure O O O O O O O O
NT-proBNP O O O O O O O O
cTnI O O O O O O O O
U A:C O O O O O O O O
cTnI, cardiac troponin I; NT-proBNP, N-terminal pro brain natriuretic peptide; Serum CRT, serum creatinine; U A:C, urinary
aldosterone-to-creatinine ratio; ECG, electrocardiogram.
a or early termination visit.
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Echocardiography
An echocardiographic examination was mandatory
for visit 1, 3, 5, 7, and 8. The investigators had
the option to perform an additional examination
at the other visits. Echocardiographic examina-
tions were performed on unsedated dogs as per
the established standard for veterinary cardiology
[16]. All measurements were taken from at least
three consecutive cardiac cycles, and the mean
was recorded. The following measurements were
taken from the right parasternal short-axis view:
LA:Ao obtained in two-dimensional view as
described by Lavall et al. [11], and left ven-
tricular diameter measured in M-mode from the
short axis with the leading edge to inner edge
method at the level of the papillary muscles. Left
ventricular normalized dimensions were calcu-
lated as described [14]. Early (E peak) and late A
transmitral inflow velocities were assessed by
spectral Doppler from the left four chamber api-
cal view.
Urinary aldosterone-to-creatinine ratio
Approximately 6 mL of urine sample were col-
lected by free catch, catheterization, or cys-
tocentesis at each visit from each dog, divided in
four aliquots and immediately frozen at 20 C.
Samples were shipped frozen once a year to a
central laboratoryae for determination of urine
aldosterone-to-creatinine ratio (U A:C). The lab-
oratory was blinded to the treatment group.
Samples were maintained at 80 C until the
measurement of urine aldosterone, which was
performed using a validated assay for canine
species,af in accordance to the procedure indi-
cated in the data sheet. Creatinine was deter-
mined using commercial biochemical assay.
NT-proBNP and cTnI
Approximately, 5 mL of venous blood were
obtained from each dog at each visit. Until
December 31, 2016, blood was collected into tubes
containing ethylenediaminetetraacetic acid and
specialized protease inhibitor to reduce the risk of
sample degradation. Blood samples collected after
January 1, 2017 were collected into tubes con-
taining only ethylenediaminetetraacetic acid.
Samples were centrifuged within 60 min after
collection, plasma was separated, divided in two
aliquots, and frozen before overnight shipment to
a central laboratory.ag Samples were then divided
into several aliquots and were frozen at 80 C.
Measurement of NT-proBNP was performed in
batches with Idexx first-generation immunoassayah
for samples collected before December 31, 2016
and with a second-generation immunoassay
methodai for sample processed after January 1,
2017. The equivalence between the two methods
has been previously reported [17].
Samples for cTnI were frozen and shipped
overnight, once a year, to a central laboratoryaj
and were stored at 80 C for batched analysis.
Concentration of cTnI was analyzed using an ELI-
SAak assay in accordance with the manufacturer’s
instructions as previously described [18].
All plasma analysis for NT-proBNP and cTnI were
carried out in duplicate and assays performance
was previously reported [18,19].
Quality of life
Quality of life was assessed by using a scoring
system based on the following parameters: body
weight, appetite, cough, exercise intolerance, and
syncope (Table 2).
Primary end point
The primary end point was the time to cardiac
death or onset of first occurrence of HF defined by
the presence of either dyspnea and/or tachypnea
(36 breaths/min at rest) that could not be
explained by another disease based on clinical
judgment by the investigator [20]. Radiographs
were performed at the last visit if the dog was
presented at the investigator clinic and if its
health condition allowed it. They were used as a
basis to either confirm pulmonary edema or to
exclude any other reason that could explain the
observed clinical signs. In case where it was not
possible to perform radiographs, owing to critical
ae Department of Veterinary Sciences, University of Torino,
Grugliasco, Italy.
af Cayman Chemical Aldosterone ELISA Kit, Cayman Chem-
icals, Ann Arbor, MI, USA.
ag IDEXX BioResearch, Vet Med Labor GmbH, Ludwigsburg,
Germany.
ah Canine Cardiopet proBNP test kit, IDEXX Laboratories
Inc., Westbrook, ME.
ai Canine Cardiopet proBNP test kit, IDEXX Laboratories Inc.,
Westbrook, ME.
aj Laboratory for clinical chemistry and transfusion medicine,
Southern A¨lvsborg Hospital, Alingsa˚s, Sweden.
ak Access Systems AccuTnI Assay, Beckman Coulter, Inc, Full-
erton, CA.
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health conditions or refusal of the owner to run
this examination, or if the dog was not directly
seen by the investigator because of a sudden
clinical deterioration (death at home, visit to their
general practitioner), diagnosis of HF was deter-
mined by the investigator based on clinical signs
observed, and/or information reported by the
owner or by other veterinarians.
Table 2 Baseline characteristics of the two treatment groups in the intention-to-treat population and their
comparison. Continuous variables are reported as mean and standard deviation (SD) when normally distributed and
as median and 75th and 25th percentile range if not. Categorical variables are reported as number (%).
Variable Treatment groups P-
ValueSpironolactone
þ Benazepril n ¼ 87
Placebo
n ¼ 92
Dogs’
characteristics
Age (years) 9.3 (2.1) 9.2 (2.1) 0.694
Sex (M/F) (%) 62/25 (71/29) 56/36 (61/39) 0.143
Breed (Mixed-
breed/CKCS/Poodle/Dachshund/
Chihuahua/Jack Russell terrier/
Bichon Frise/Other) (%)
31/20/5/6/4/1/3/17
(36/23/6/7/5/1/3/19)
41/14/7/6/3/4/2/15
(45/15/8/7/3/4/2/16)
e
Mixed breed vs other breeds 31/56 (36/64) 41/51 (45/55) 0.223
CKCS vs other breeds 20/67 14/78 0.185
Dose of test
medication
Daily dose medication
(spironolactone/benazepril; mg/kg)
2.8  0.6/0.3  0.1 NA e
Quality of
life and
respiratory
variables
Appetite (normal (1), increased (2),
decreased (3), anorexia (4)) (%)
84/3/0/0 (97/3/0/0) 91/1/0/0 (99/1/0/0) 0.285
Cough (none (0)/occasional
(1)/frequent (2)/persistent (3)) (%)
72/15/0/0 (83/17/0/0) 72/20/0/0 (78/22/0/0) 0.448
Exercise intolerance (No (0)/Yes
(1)) (%)
85/2 (98/2) 91/1 (99/1) 0.528
Syncope (none (0)/4 per
month (1)/>4 per month (2)) (%)
86/1/0 (99/1/0) 90/2/0 (98/2/0) 0.594
Physical
examination
variable
Body weight (kg) 10.0  4.2 9.8  4.2 0.770
Body condition score (too thin (1e3),
ideal (4e5), too heavy (6e9)) (%)
3/63/21 (4/72/24) 4/62/24 (4/69/27) 0.806
Heart rate (beats/min) 117 (20) 121 (20) 0.290
Femoral pulse (normal (1)/
weak (2)/pulse deficit (3)) (%)
86/1/0 (99/1/0) 91/1/0 (99/1/0) 0.968
Dyspnea (no (0)/on effort (1)/at rest (2)
(%)
87/0/0 (100/0/0) 92/0/0 (100/0/0) e
Tachypnea (No (0)/Yes (1)) (%) 85/2 (98/2) 89/3 (97/3) 0.696
Respiratory sinus arrhythmia (No (0)/Yes
(1)) (%)
40/47 (46/54) 41/51 (45/55) 0.850
Systolic blood pressure (mmHg) 143  17 143  16 0.945
Heart murmur intensity (mild (1e2)/
moderate (3e4)/severe (5e6)) (%)
2/76/7 (3/89/8) 4/76/12 (4/83/13) 0.207
Diagnostic
imaging
variables
VHS 11.2  0.9 11.2  0.8 0.921
LVEDDn 1.9  0.2 1.9  0.2 0.740
LVESDn 1.0  0.2 1.1  0.2 0.349
LA:Ao 1.9  0.2 1.9  0.2 0.564
E peak (m/s) 1.0  0.2 1.0  0.3 0.462
A peak (m/s) 0.8  0.2 0.8  0.2 0.617
Laboratory
variables
Urinary creatinine (mg/dL) 170.7  109.3 182.2  127.8 0.542
Urinary aldosterone (pg/mL) 642.6  473.8 657.3  483.3 0.845
U A:C 0.4  0.5 0.4  0.5 0.902
NT-proBNP (pmol/L) 1150 (625e1718) 880 (632e1731) 0.277
HS cTnI (ng/mL) 0.04  0.10 0.04  0.05 0.739
A peak, late transmitral peak velocity; E peak, early transmitral peak velocity; LVEDDn, normalized left ventricular end-diastolic
diameter; LVESDn, normalized left ventricular end-systolic diameter; LA:Ao, left atrium-to-aortic root ratio; VHS, vertebral heart
scale; U A:C, urinary aldosterone-to-creatinine ratio; NT-proBNP, N-terminal pro brain natriuretic peptide.
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At the end of the study, an independent
committee composed of three board-certified
cardiologistsal, blinded to the treatment group
and not involved in the study, reviewed all
reasons for ending the study, and confirmed
whether or not each individual reached the
primary end point. All clinical data and radio-
graphs were provided to this committee. In case
of discrepancy between experts in the inde-
pendent committee, the majority opinion was
considered as the final decision (i.e. two experts
vs one).
The independent committee provided the SCDS
blinded data review committee (D.C., F.M., M.B.,
M.P.) with its final decisions. In case of discrepancy
between the independent committee and the SCDS
blinded data review committees, cases were dis-
cussed again and the opinion of the majority of all
committees’ members was considered as the final
decision.
Secondary end points
The secondary end points of the study included
evaluation of effect of treatment on progression of
the disease based on echocardiographic and
radiographic parameters, systolic blood pressure
values, and variations of cardiac biomarkers (NT-
proBNP and cTnI). Adverse events in the two
groups were compared and analyzed, whereas a
time-to-deterioration analysis was performed for
quality of life parameters. The effects of treat-
ment on urinary aldosterone and U A:C were also
assessed.
Data management
All clinical observations and project activities were
carefully recorded on the case report form. All
study documentation, including the protocol, the
raw data, and the statistical and clinical electronic
reports, were stored at the sponsor’s facility.
Accuracy of the recorded data was checked on site
by the appointed monitor. All data were entered
into a database. After verification of the accuracy
of data entries, a medical review was performed
by the SCDS data review committee. After the
database was locked, it was transferred to the
independent statistician (K.L.). Blinding was
maintained during data entry, audit, and stat-
istical analysis.
Statistical methods
The projected number of dogs required for the
study was determined by the probability for an
untreated dog to progress to HF during the study
period. Based on previous published data, a dog
has 60% of chance of not progressing into HF in a
3.5 years period [21]. Based on these data, a
power analysis indicated that it was necessary
to include 200 dogs to show significance with an
alpha of 0.05 and a beta of 0.8 based upon a
22% difference in the time free of HF. Assuming
a hypothetical 20% of withdrawal from the
study, the inclusion of 240 animals was consid-
ered to represent a safe margin to identify any
treatment effect in the 3.5 year follow-up
period.
Baseline descriptive statistics are reported as
mean and standard deviation for normally dis-
tributed variables and median and interquartile
range for non-normally distributed variables. The
distribution of residuals was assessed by visual
inspection followed by the Kolmogorov-Smirnoff
test. Between-groups analyses of baseline varia-
bles were performed using analysis of variance as
error residuals were normally distributed. Inter-
action of categorical clinical covariates was car-
ried out by analysis of variance, whereas
interaction of categorical and continuous echo-
cardiographic variables was carried out by anal-
ysis of covariance generating least square means
for analysis. Analyses for proportions of catego-
rical variables were evaluated with a Chi-squared
test or Fisher’s exact analysis as appropriate.
Date of study entry was the time of clinical
diagnosis, and data obtained at this time were
evaluated in baseline analyses. Time-to-event
analyses were carried out in univariate by way
of Kaplan-Meier product limit estimates. Cox
semiparametric regression models were used to
generate univariate models. Covariates found
significant were used in conjunction with treat-
ment for multivariable models. The multivariable
models were analyzed using interaction terms
using enter and stepwise regression and enter
method. Multicollinearity was assessed by var-
iance inflation factor analysis and deemed
acceptable. Covariates for the multivariate
model were presented as both continuous and
categorical. Continuous variables were catego-
rized based on spline assessment, clinical
rationale, and previous literature. Tests for pro-
portionality were carried out by visual inspection
of Schoenfeld residuals, negative log estimated
survival distribution function, and formal
hypothesis testing of covariate by log (time)al Sonja Fonfara, Dan Hogan and Matthias Schneider.
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interactions followed by Wald Chi-squared sta-
tistics and deemed proportional. Statistical dif-
ferences between Kaplan-Meier product limit
estimates strata were determined by a log-rank
test. Time-to-event survival time analyses rep-
resented time from study entry to end date.
Quality of life end points were defined as first
date to clinical score deterioration or heart fail-
ure. Cases lost to follow-up or remaining alive
were right censored. Analyses were performed
with statistical software.am P < 0.05 was deemed
significant.
During the course of the DELAY study, a related
clinical trial reported the efficacy of pimobendan
in a similar population of dogs [5]. For ethical
reasons, an unplanned ad hoc interim analysis was
carried out in the DELAY study. The interim
analysis based upon a stopping probability at first
look of 0.05 alpha suggested study continuation
based upon the assumption that a required num-
ber of events were observed by the end of the
predefined study follow-up period. After the
interim analysis, owners of dogs still alive were
informed about results of the EPIC trial [5] and
were given the option of withdrawing their dog
from the study to start administration of pimo-
bendan. The final look of unadjusted P indicated
an adjusted significance of 0.0475 alpha
(0.95  0.05).
Results
One hundred eighty-four dogs were enrolled and
183 randomized to receive trial treatment (Fig. 1).
The median age of patients enrolled per inves-
tigator was 7.5 years (range, 5e13). Eighteen dif-
ferent breeds were included, with mixed breeds
being the most represented (n ¼ 72; 40%), fol-
lowed by Cavalier King Charles Spaniels (n ¼ 34;
19%), Poodles (n ¼ 12; 7%), Dachshunds (n ¼ 12;
7%), Chihuahuas (n ¼ 7; 4%) Jack Russell terriers
(n ¼ 5; 3%), and Bichon Frise (n ¼ 5; 3%). No dif-
ferences were observed between the two groups
at inclusion. In the treatment group, dogs received
a mean daily dose of 2.8  0.6 mg/kg of spi-
ronolactone and of 0.3  0.1 mg/kg of benazepril.
One dog was treated with pimobendan for less
than two weeks before inclusion in the study.
However, the treatment discontinued one month
before the enrollment in agreement with the study
design. A full summary of the ITT population
characteristics is reported in Table 2.
In the PP population, the median duration in the
study was 561 days (95% confidence interval [CI]:
142e977) and 75 dogs (44.9%) reached the com-
posite primary end point (42 in the study group
[51.2%] and 33 in the placebo group [38.4%],
p ¼ 0.46). Twenty-eight dogs (15.3%) died for
cardiac causes (15 in the study group [20%] in the
study group and 13 in the placebo group [17.3%],
p ¼ 0.88). The median time in the study of dogs
reaching the primary end point was 1045 days [95%
CI: 766-not available (NA)]. Ninety-three dogs
Fig. 1 Flow chart reporting the outcome for the 184 dogs randomized in the study.
am SAS 9.4, 2016 Cary, NC: SAS Institute Inc.
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were censored from the analysis of end point (40
dogs in the treatment group and 53 in the placebo
group), including 36 dogs that were still asympto-
matic at the end of the study (17 in the treatment
group and 19 in the placebo group). Twenty-five
dogs (8 in the treatment and 17 in the placebo
group) were censored from the study because of
owner’s or investigator’s decision (Table 3).The
other causes of censoring are reported in Fig. 1.
The estimated median time to primary end point
was 902 days (95% CI: 682-NA) for the treatment
group and 1139 days (95% CI: 732-NA) for the
control group (Fig. 2). There was no difference
between groups in reaching the primary end point
(p ¼ 0.456). In the univariate Cox proportional
hazard analysis, six variables were associated with
Table 3 Main reasons for censoring due to dog owner or investigator decision.
Owner
decision
Spironolactone benazepril n ¼ 7 Placebo n ¼ 14
No reason mentioned n ¼ 2 No reason mentioned n ¼ 3
Owner not motivated, did not want to
continue, decided not to come back n ¼ 3
Owner not motivated, did not want to continue,
decided not to come back n ¼ 3
Owner’s personal problems n ¼ 2 Owner’s personal problems n ¼ 2
Owner concerns about study protocol: safety of
study drugs or examinations n ¼ 2
Owner wanted to start forbidden cardiac
treatment n ¼ 2
The owner decided to stop the study and
suspicion of concomitant disorder n ¼ 2
Investigator
decision
Spironolactone benazepril n ¼ 1 Placebo n ¼ 3
Investigator decision due to a suspected owner’s
lack of compliance n ¼ 1
Suspicion of concomitant disorder n ¼ 1
Wrong diagnosis and prescription of a forbidden
cardiac concomitant treatment n ¼ 1
Investigator decision due to a suspected owner’s
lack of compliance n ¼ 1
Fig. 2 Kaplan-Meier survival curves plotting the estimated percentage of dogs in each group in the per protocol
population that have not reached the primary end point (heart failure or cardiac death) against time. There were 82
dogs in the benazepril spironolactone group and 86 dogs in the placebo group.
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an increased risk for reaching the primary end
point at p < 0.05 (Table 4). All these variables did
not show any interaction and were not associated
with treatment effects as demonstrated by the
Cox multivariable analysis. Two of these variables,
10% LVEDDn increment (hazard ratio: 1.434, 95%
CI: 1.264e1.626, p < 0.001) and 5 beats per
minute heart rate increment (hazard ratio: 1.003,
95% CI: 1.001e1.005, p ¼ 0.012), were independ-
ent predictors of an event in the Cox stepwise
multivariate analysis.
An effect over the time of treatment with spi-
ronolactone and benazepril on several variables
associated with cardiac remodeling was observed.
The heart rate, LA:Ao, LVEDDn, and E peak
velocity were lower at the end of study in the
treatment group compared with the placebo
group. The normalized left ventricular end-systolic
diameter was smaller for V4 and V5 but was not
different at the end of the follow-up. The verte-
bral heart scale was smaller for V5, V6, and V7 and
nearing significant (p ¼ 0.053) at the end of the
study (Fig. 3, Table 5). The NT-proBNP, but not
cTnI, was lower at the end of the study in the
treatment group compared with the placebo group
(Fig. 4, Table 6). The serum creatinine was not
different among the groups at the time of enroll-
ment in the study, and it did not change within and
between groups over the time (Table 6). The uri-
nary aldosterone concentrations were higher in
the treatment group at the end of the study. The U
A:C increased in both groups over the time (Fig. 4,
Table 6).
In the ITT population, the median survival time
was 925 days (95% CI: 789e1251). There were no
differences in the number of adverse events
between groups. There were 45 (44%) adverse
events in the treatment group and 57 (56%) in the
placebo group (p ¼ 0.235). Table 7 provides detail
of adverse events for each group. Concomitant
treatments for each group are detailed in Table 8.
The estimated median time to primary end
point was 902 days (95% CI: 656e1251) for the
treatment group and 925 days (95% CI: 629-NA) for
the placebo group (Fig. 5). Overall mortality for
the ITT population was 31 of 179 dogs (17.4%), 15
(8.4%) in the spironolactone and benazepril group,
and 16 (8.9%) for the placebo group.
There were no differences in quality of life
parameters between the two groups.
Discussion
The DELAY study failed to demonstrate an effect of
combined spironolactone-benazepril treatment in
delaying the onset of HF in this population of
asymptomatic dogs affected by MMVD despite
successful blockade of the mineralocorticoid
receptors, as demonstrated by the increased uri-
nary aldosterone level, reduction or even reverse
in cardiac remodeling on diagnostic imaging, and
Table 4 Probability to reach the primary end point in Cox proportional univariate analysis in the per protocol
population. P-values <0.05 were considered significant.
HR 95% CI P value
Spironolactone/benazepril treatment 1.189 0.753e1.877 0.457
Body weight 1.015 0.961e1.072 0.603
Age 1.067 0.957e1.190 0.245
Heart rate (for 5 bpm increment) 1.002 1.000e1.005 0.040
SBP (for 10 mmHg increment) 1.001 0.999e1.002 0.430
CKCS (Yes) 1.226 0.661e2.274 0.518
VHS (for 0.1 increment) 1.380 1.059e1.798 0.017
LA:AO (for 10% increment) 1.129 1.030e1.237 0.010
LVEDDn (for 10% increment) 1.402 1.240e1.586 <0.001
LVESDn (for 10% increment) 0.958 0.838e1.094 0.522
E peak (for 10% increment) 1.101 1.010e1.200 0.028
A peak (for 10% increment) 1.087 0.972e1.215 0.145
NT-proBNP pmol/L (for 100 increment) 1.033 1.013e1.053 <0.001
cTnI ng/mL (for 10% increment) 0.913 0.625e1.334 0.639
U A pg/mL 1.000 0.999e1.000 0.083
U A:C 0.568 0.312e1.035 0.065
A peak, late transmitral peak velocity; bmp, beats per minute; CKCS, Cavalier King Charles spaniel; cTnI, cardiac troponin I; CI,
confidence interval; E peak, early transmitral peak velocity; HR, hazard ratio; LVEDDn, normalized left ventricular end-diastolic
diameter; LVESDn, normalized left ventricular end-systolic diameter; LA:Ao, left atrium-to-aortic root ratio; NT-proBNP, N-ter-
minal pro natriuretic peptide; SBP, systolic blood pressure; U A, urine aldosterone; U A:C, urinary aldosterone-to-creatinine ratio.
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lower concentrations of NT-proBNP in the treat-
ment group at the end of the follow-up.
The lack of prolongation of the asymptomatic
phase in the treatment group might be explained
by several considerations. First, dogs with pre-
clinical MMVD represent a heterogeneous group of
animals with some individuals presenting a slow
progression of the disease and other rapidly
developing HF [4]. In an effort to enroll a more
homogeneous group of dogs, the DELAY study had
specific echocardiographic inclusion criteria, as
had other previous studies [5,6]. However, these
criteria still allow inclusion of dogs affected by a
mild disease, as well as dogs with a more advanced
condition. In our study, 35% of dogs had a LA:Ao <
1.8 and 27% a LVEDDn <1.8, suggesting that they
were affected by a relative mild form of the dis-
ease and had therefore a lower risk of reaching the
Fig. 3 Summary of analysis of covariance for heart rate and parameters of cardiac remodeling. There is a treatment
effect over placebo for all variables (Table 4) over the time (*P < 0.05, **P < 0.001). BPM, beats per minute; E peak,
early transmitral peak velocity; LA:Ao, left atrium-to-aortic root ratio; LVEDDn, normalized left ventricle end-
diastolic diameter; LVESDn, normalized left ventricular end-systolic diameter; VHS, vertebral heart score.
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Table 5 Summary of effects of treatment over time for radiographic and echocardiographic parameters. Values are reported as adjusted mean and standard
error. The number of cases remaining in the study at each time point for the placebo and treatment were: V1, 81:86; V2, 73:69; V3, 59:60; V4, 47:44; V5, 36:34; V6,
33:26; V7, 24:24; and V8, 20:19. P-values <0.05 were considered significant.
Visit Tx HR bpm P value VHS P value LA:Ao P value LVEDDn P value LVESDn P value E peak (m/sec) P value
V1 SB 121  1.79 0.982 11.3  0.07 0.899 1.92  0.03 0.763 1.90  0.02 0.440 1.04  0.02 0.502 0.98  0.02 0.123
P 121  1.79 11.3  0.07 1.91  0.03 1.92  0.02 1.05  0.02 1.03  0.02
V2 SB 121  1.42 0.482 11.3  0.06 0.685 1.90  0.02 0.284 1.89  0.02 0.066 1.04  0.01 0.249 0.98  0.02 0.020
P 122  1.42 11.3  0.06 1.94  0.02 1.93  0.02 1.06  0.01 1.04  0.02
V3 SB 121  1.20 0.104 11.3  0.05 0.251 1.88  0.02 0.003 1.88  0.01 0.002 1.05  0.01 0.085 0.98  0.02 0.001
P 124  1.21 11.4  0.05 1.96  0.02 1.94  0.01 1.08  0.01 1.06  0.02
V4 SB 121  1.20 0.017 11.3  0.05 0.074 1.87  0.02 <0.001 1.87  0.01 <0.001 1.06  0.01 0.037 0.97  0.02 <0.001
P 125  1.24 11.4  0.05 1.99  0.02 1.96  0.01 1.09  0.01 1.06  0.02
V5 SB 121  1.44 0.009 11.3  0.06 0.042 1.85  0.02 <0.001 1.86  0.02 <0.001 1.06  0.01 0.037 0.97  0.02 <0.001
P 126  1.49 11.5  0.06 2.01  0.02 1.97  0.02 1.10  0.01 1.06  0.02
V6 SB 121  1.82 0.009 11.3  0.07 0.040 1.83  0.03 <0.001 1.85  0.02 <0.001 1.07  0.02 0.055 0.97  0.02 0.002
P 128  1.89 11.5  0.08 2.04  0.03 1.98  0.02 1.11  0.02 1.07  0.02
V7 SB 121  2.27 0.012 11.3  0.09 0.046 1.81  0.03 <0.001 1.84  0.02 <0.001 1.07  0.02 0.079 0.97  0.03 0.005
P 129  2.35 11.5  0.09 2.06  0.03 1.99  0.03 1.12  0.02 1.08  0.03
V8 SB 121  2.75 0.016 11.3  0.11 0.054 1.79  0.04 <0.001 1.84  0.03 <0.001 1.08  0.02 0.105 0.97  0.03 0.011
P 130  2.85 11.6  0.12 2.09  0.04 2.00  0.03 1.13  0.02 1.09  0.03
Bpm, beats per minute; E peak, early transmitral peak velocity; HR, heart rate; LA:Ao, left atrium-to-aortic root ratio; LVEDDn, normalized left ventricular end-diastolic diameter;
LVESDn, normalized left ventricular end-systolic diameter; P, placebo; SB, spironolactone benazepril; Tx, treatment; VHS, vertebral heart scale.
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primary end point during follow-up. Studies testing
efficacy of a treatment in a low-risk population
normally require a higher number of patients or a
longer observation period to demonstrate an
effect on the natural history of the disease [22].
Pharmacological failure would be another poten-
tial explanation for this outcome. However, this
seems unlikely because the increased urinary
aldosterone in the treatment group indicates suc-
cessful pharmacological blockade of miner-
alocorticoid receptors. Furthermore, the
effects of treatment on echocardiographic and
radiographic variables of cardiac remodeling and
level of NT-proBNP would suggest an adequate
pharmacological action on the RAAS. Finally, the
DELAY study had a relatively small population of
Cavalier King Charles spaniel compared with a
similar trial [5]. Indeed, it has been reported that
this breed has a faster progression from the pre-
clinical to the clinical phase of the disease [23,24],
therefore it is possible that this has influenced the
rate of events in our study.
Despite failing to show a clinical benefit on
the time to the onset of HF, the DELAY study
suggests beneficial effects of the chronic
treatment with combined spironolactone and
benazepril. These include the slower progression
or even improvement of echocardiographic and
radiographic parameters in the treatment group.
The vertebral heart scale, LA:Ao, LVEDDn, and
E peak velocity of mitral valve inflow, which
are all negative predictive parameters of out-
come in previous studies [5,21,25,26], were sig-
nificantly lower in the treatment group than the
placebo group during the observation period.
Furthermore, NT-proBNP concentration increases
in the placebo group but not in dogs receiving
treatment. The NT-proBNP is a biomarker that
reflects myocardial stretch and has been asso-
ciated with the severity of the disease and
clinical outcome in previous studies [27e31]. All
together, these results suggest that the com-
bined spironolactone and benazepril treatment
has a significant effect over time to reduce, or
even reverse, cardiac remodeling. cTnI levels
were not affected by treatment, confirming that
there is not significant underlying myocardial
damage during the preclinical phase of MMVD
[18,32].
Results of this study suggest that the RAAS is
activated in dogs with preclinical MMVD as the
diseases progresses. This is demonstrated by the
Fig. 4 Summary of analysis of covariance for cardiac biomarkers, urinary aldosterone and urinary aldosterone-to-
creatinine ratio. There is a treatment effect over placebo (*P < 0.05, **P < 0.001) for N-terminal pro brain natriuretic
peptide, and the urinary aldosterone is significantly higher in the treatment group over the time (Table 4). NT-proBNP,
N-terminal pro natriuretic peptide; cTnI, cardiac troponin I; U A, urine aldosterone; U A:C: urinary aldosterone-to-
creatinine ratio.
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Table 6 Summary of effects of treatment over time on cardiac biomarkers, urinary aldosterone, and urinary aldosterone-to-creatinine ratio. Values are reported
as adjusted mean and standard error. P-values <0.05 were considered significant.
Visit Tx NT-proBNP pmol/L P value cTnI
ng/mL
P value Serum creat. mg/dL P value U A
pg/mL
P value U Creat.
mg/dL
P value U A:C
mg/g
P value
V1 SB 1463  98 0.415 0.04  0.02 0.632 66.0  1.9 0.979 822  111 0.754 177.9  8.6 0.680 0.60  0.09 0.758
P 1349  98 0.04  0.02 66.0  2.0 872  110 182.9  8.5 0.56  0.09
V2 SB 1487  78 0.776 0.03  0.02 0.483 66.2  1.5 0.753 1038  88 0.517 172.3  6.8 0.960 0.75  0.07 0.560
P 1456  78 0.04  0.02 66.8  1.6 957  87 172.8  6.8 0.70  0.07
V3 SB 1512  66 0.588 0.03  0.02 0.335 66.3  1.3 0.430 1253  74 0.047 166.7  5.8 0.622 0.91  0.06 0.361
P 1563  66 0.13  0.02 67.7  1.3 1043  75 162.6  5.8 0.84  0.06
V4 SB 1537  67 0.165 0.08  0.03 0.263 66.4  1.3 0.230 1469  76 0.002 161.0  5.9 0.311 1.07  0.06 0.269
P 1670  68 0.04  0.03 68.6  1.3 1129  78 152.5  6.1 0.97  0.06
V5 SB 1562  81 0.063 0.03  0.03 0.285 66.7  1.5 0.176 1684  92 <0.001 155.4  7.1 0.202 1.23  0.07 0.275
P 1777  82 0.03  0.03 69.5  1.5 1214  95 142.3  7.4 1.11  0.07
V6 SB 1587  102 0.042 0.03  0.03 0.347 66.7  1.9 0.178 1899  117 <0.001 146.8  8.9 0.176 1.38  0.09 0.315
P 1884  104 0.04  0.04 70.4  1.9 1300  121 132.2  9.4 1.25  0.09
V7 SB 1612  127 0.037 0.03  0.04 0.410 66.8  2.4 0.194 2115  146 <0.001 144.1  11.2 0.172 1.54  0.11 0.356
P 1991  129 0.05  0.03 71.2  2.4 1386  150 122.0  11.7 1.39  0.12
V8 SB 1637  154 0.037 0.03  0.04 0.464 67.0  2.9 0.211 2330  178 <0.001 138.5  13.6 0.175 1.70  0.14 0.392
P 2098  157 0.06  0.04 72.1  2.9 1472  181 111.9  14.2 1.53  0.14
cTnI, cardiac troponin I; NT-proBNP, N-terminal pro natriuretic peptide; P, placebo; SB, spironolactone benazepril; Serum Creat, serum creatinine; Tx, treatment; U A, urine aldos-
terone; U A:C, urinary aldosterone-to-creatinine ratio; U Creat, urine creatinine.
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increase of U A:C in the placebo group. The
observed increased U A:C in the treatment group
cannot be interpreted as evidence of ABT because
of the effects on spironolactone on aldosterone
metabolism. Aldosterone urine concentration is
expected to be increased in patients receiving
spironolactone as the result of mineralocorticoid
receptor blockade. Ames et al. [12] have reported
that U A:C ratio is significantly increased in dogs
affected by MMVD with or without HF treated with
spironolactone in addition to furosemide, pimo-
bendan, and an ACEi compared with dogs treated
with the standard triple therapy. Although
the U A:C ratio does not differ between the
group, urinary aldosterone concentration are
significantly higher starting from visit two, sug-
gesting a chronic pharmacological effect of the
drug because the renal function was similar in
both groups. The DELAY study also suggests that
the pharmacological modulation of RAAS requires
time to demonstrate its beneficial effects as
indicated by the echocardiographic variable of
cardiac remodeling and level of biomarkers
that become different just after 12e18 months of
treatment. Such results can be explained by the
long time required by the RAAS pharmacological
modulation to take effect, as reported in several
human and veterinary clinical trials [33e35], as
well as by the slow progression of the disease.
Previous studies using an ACEi alone have not only
failed to demonstrate a convincing effect on the
time to the onset of HF in dogs with preclinical
MMVD, but they also did not show any effect
on cardiac remodeling assessed by diagnostic
imaging [6,7]. It is possible that a more complete
blockade of the RAAS by the combined treatment
Table 7 Adverse events and serious adverse events (adverse event which results in death, life-threatening,
persistent disability) experienced by the dogs in the spironolactone þ benazepril group and the placebo group
(dogs could experience more than one adverse event or more than one clinical sign at the time of the adverse
event).
Spironolactone þ benazepril Placebo P-
valueAdverse
event
Serious adverse
event
Adverse
event
Serious
adverse
event
Blood and lymphatic
system disorders
1 0 1 0 0.866
Cardiovascular system
disorders
5 1 5 3 0.919
Digestive tract
disorders
6 1 10 0 0.789
Endocrine system
disorders
2 0 1 0 0.425
Eye disorders 4 0 0 0 0.022
Hepatobiliary disorders 0 0 2 0 0.204
Musculoskeletal
disorders
5 0 1 1 0.132
Neurological disorders 3 2 5 5 0.362
Renal and urinary
disorders
3 0 2 3 0.695
Reproductive system
disorders
1 0 1 0 0.866
Respiratory tract
disorders
2 0 4 3 0.166
Skin and appendages
disorders
2 0 3 0 0.849
Systemic disorders 4 1 6 0 0.925
Unclassifiable event 2 0 1 0 0.425
40 5 42 15
Total of events (serious
and non-serious)
45 57 0.235
Number of dogs
experiencing at least
1 event
13 21 0.179
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with an ACEi and a mineralocorticoid receptor
antagonist is able to effectively reduce its bio-
logical effects on cardiac remodeling [9], and
the results of this study appear to confirm this
hypothesis.
Limitations
The first limitation of this study was the insuffi-
cient number of cases of an advanced preclinical
population enrolled, which affected the statistical
power of the study as aforementioned. The second
limitation was the unplanned prolonged recruit-
ment period, which may have caused loss of
motivation in recruiting cases, together with new
findings becoming available. The third limitation is
represented by the percentage of cases that
reached the primary end point. In addition to the
anticipated dropout ratio, some owners elected to
abandon the study to administer pimobendan to
their dogs after the publication of the clinical
efficacy of administration of this drug in a com-
parable canine population. The length of the
observational period may also appear excessively
long for some owners, especially in apparently
Table 8 Concomitant treatments related to end of study, end point, or premature withdrawal.
Spironolactone benazepril (n [ 87) Placebo (n [ 92)
Cardiac cause Number of dogs N [ 5 Number of dogs N [ 2
Treatments
prescribed (nb
treatments)
Reasons for
administration
Treatments
prescribed (nb
treatments)
Reasons for
administration
Cardiac treatments Antiarrhythmic (2) Atrial fibrillation Inodilator (1) Pulmonary
hypertension
Ventricular
arrhythmia
ACEi (1) -MRA (1) Pulmonary
hypertension
Pulmonary veins
congestion
Non-cardiac
treatments
Cough suppressant
(2)
Cough Antiinfectives (1) Diarrhea
Gastroprotector
(1)
Diarrhea
Non-cardiac
cause
Number of dogs N [ 4 Number of dogs N [ 4
Treatments
prescribed (nb
treatments)
Reasons for
administration
Treatments
prescribed (nb
treatments)
Reasons for
administration
Cardiac treatments / /
Non-cardiac
treatments
Antiinfectives (3) Encephalitis Antiinfectives (2) Urinary tract
infection
Gastrointestinal
syndrome
Tracheitis
Anxiolytics (1) Encephalitis Anxiolytics (1) Urinary tract
obstruction
Corticosteroids (2) Lymphoma Electrolytes (1) Dehydration
Encephalitis Corticosteroids (4) Neurological
symptoms
Insulin/
hormonotherapy
(2)
Diabetes Cough
Hyperadrenocorticism Paralysis
Antiemetic (1) Gastrointestinal
syndrome
Pain
Gastroprotector
(1)
Gastrointestinal
syndrome
NSAIDs (1) Tracheitis
Opioids (1) Abdominal pain Opioids (1) Pain
Gastroprotector
(1)
Gastroprotection
ACEi, angiotensin-converting enzyme inhibitors.
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healthy dogs, affecting their overall compliance.
Finally, the presence of significant systemic dis-
ease was based on the assessment made by the
investigators and this not always included a com-
plete hemogram and serum biochemistry.
As disclosed in other studies [5,6], diagnosis of
HF and confirmation of cardiac-related death
represents a challenge. In particular, verification
of HF based on thoracic radiographs is often
controversial, despite independent blinded ver-
ification of the primary end point. For this reason,
in this study, we used the term HF rather than
congestive HF as primary end point. Moreover, not
all diagnoses of the primary end point were sup-
ported by radiographic evidence of HF (e.g. sud-
den death, presentation to emergency clinics,
etc). In such cases, a presumptive diagnosis of HF
was based on clinical assessment and clinical his-
tory but this was equally observed in both groups
and should not have affected the final results.
Conclusions
This study failed to demonstrate a prolongation of
the asymptomatic phase of the disease in
this population of dogs. Nevertheless, the treat-
ment appears effective in reducing or even in
reverse cardiac remodeling as indicated by various
cardiac imaging parameters and NT-proBNP con-
centrations. Chronic administration of combined
spironolactone and benazepril treatment in dogs
with preclinical MMVD and cardiac enlargement is
safe and well tolerated. The significant effect of
this treatment on secondary end points could be of
clinical relevance and merits further study.
Funding
This project was funded by Ceva Sante´ Animale,
Libourne, France. Assessment of N-terminal pro
brain natriuretic peptide was sponsored by IDEXX
BioResearch, Vet Med Labor GmbH, Ludwigsburg,
Germany.
Conflicts of Interest Statement
Two authors, E.G. and C.G-.P., are representatives
of Ceva Sante´ Animale. All the other authors have
received funding from Ceva Sante´ Animale within the
last 5 years for some or all of the following activities:
research, travel, speaking fees, consultancy fees,
and preparation of educational materials.
Acknowledgments
The authors thank Dan Hogan, Sonja Fonfara, and
Matthias Schneider, members of the end point val-
idation committee. Jens Ha¨ggstro¨m for performing
blind review of thoracic radiographs. Lisbeth Høier
Olsen, Nuala Summerfield, and Faiez Zannad were
the members of the interim analysis committee.
Cristina Vercelli and Giovanni Re for performing and
helping with the interpretation and validation of
urinary aldosterone and urinary aldosterone-to-
creatinine ratio. The authors also thank the dis-
pensers of the study Laura Barham, Ezio Bianchi,
Francesco Birettoni, Donna Boddie, Barbara Bruno,
Giulia Calogero, Vicki Cooper, Laura Cortese,
Antonella Destino, Joanne Farminer, Silvia Fraboni,
GianMarco Gerboni, Sarah King, Teja Knapp,
Simone Longobardi, Kay Naden, Mark Norcott, Ste-
fano Oricco, Giovanna Palamara, Helen Poser, Amy
de Roy, Vanessa Scanu, Maria Serena Scotto, Bar-
bara Sortini, Laura Toscano, Lieke Van Densen. The
authors thank Khnata Lamchemmach, Anne-Marie
Piron, Laetitia Silva from Ceva Sante´ Animale for
technical assistance, as well as the monitors, Isa-
belle Crosset and Alessandra Gagnatelli. The
authors would also like to thank all the dog owners
who agreed to participate in the study.
References
[1] Egenvall A, Bonnett BN, Hedhammar A, Olson P. Mortality
in over 350,000 insured Swedish dogs from 1995-2000: II.
Fig. 5 Kaplan-Meier survival curves plotting the esti-
mated percentage of dogs in each group in the intention-
to-treat population that have not reached the primary
end point (heart failure or cardiac death) against time.
There were 87 dogs in the benazepril spironolactone
group and 92 dogs in the placebo group.
Spironolactone and benazepril in preclinical mitral valve disease 51
Breed-specific age and survival patterns and relative risk
for causes of death. Acta Vet Scand 2005;46:121e36.
[2] Borgarelli M, Buchanan JW. Historical review, epidemiol-
ogy and natural history of degenerative mitral valve dis-
ease. J Vet Cardiol 2012;14:93e101.
[3] Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S,
Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V,
Stepien R. Guidelines for the diagnosis and treatment of
canine chronic valvular heart disease. J Vet Intern Med
2009;23:1142e50.
[4] Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G,
Tarducci A, Haggstrom J. Survival characteristics and
prognostic variables of dogs with preclinical chronic
degenerative mitral valve disease attributable to
myxomatous degeneration. J Vet Intern Med 2012;26:
69e75.
[5] Boswood A, Haggstrom J, Gordon SG, Wess G, Stepien RL,
Oyama MA, Keene BW, Bonagura J, MacDonald KA,
Patteson M, Smith S, Fox PR, Sanderson K, Woolley R,
Szatmari V, Menaut P, Church WM, O’Sullivan ML,
Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL,
Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH,
Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y,
Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A,
Watson P. Effect of pimobendan in dogs with preclinical
myxomatous mitral valve disease and cardiomegaly: the
EPIC study-A randomized clinical trial. J Vet Intern Med
2016;30:1765e79.
[6] Atkins CE, Keene BW, Brown WA, Coats JR, Crawford MA,
DeFrancesco TC, Edwards NJ, Fox PR, Lehmkuhl LB,
Luethy MW, Meurs KM, Petrie JP, Pipers FS, Rosenthal SL,
Sidley JA, Straus JH. Results of the veterinary enalapril
trial to prove reduction in onset of heart failure in dogs
chronically treated with enalapril alone for compensated,
naturally occurring mitral valve insufficiency. J Am Vet
Med Assoc 2007;231:1061e9.
[7] Kvart C, Haggstrom J, Pedersen HD, Hansson K, Eriksson A,
Jarvinen AK, Tidholm A, Bsenko K, Ahlgren E, Ilves M,
Ablad B, Falk T, Bjerkfas E, Gundler S, Lord P, Wegeland G,
Adolfsson E, Corfitzen J. Efficacy of enalapril for pre-
vention of congestive heart failure in dogs with myx-
omatous valve disease and asymptomatic mitral
regurgitation. J Vet Intern Med 2002;16:80e8.
[8] Sato A, Saruta T. Aldosterone breakthrough during
angiotensin-converting enzyme inhibitor therapy. Am J
Hypertens 2003;16:781e8.
[9] Cannavo A, Bencivenga L, Liccardo D, Elia A, Marzano F,
Gambino G, D’Amico ML, Perna C, Ferrara N, Rengo G,
Paolocci N. Aldosterone and mineralocorticoid receptor
system in cardiovascular physiology and pathophysiology.
Oxid Med Cell Longev 2018;2018:1204598.
[10] Park SM, Kim MN, Kim S, Shim WJ. Serum aldosterone is
related to left ventricular geometry and function in young
adults with never-treated primary hypertension. J Clin
Med 2019;8.
[11] Lavall D, Selzer C, Schuster P, Lenski M, Adam O,
Schafers HJ, Bohm M, Laufs U. The mineralocorticoid
receptor promotes fibrotic remodeling in atrial fibrillation.
J Biol Chem 2014;289:6656e68.
[12] Ames MK, Atkins CE, Eriksson A, Hess AM. Aldosterone
breakthrough in dogs with naturally occurring myxomatous
mitral valve disease. J Vet Cardiol 2017;19:218e27.
[13] Hansson K, Haggstrom J, Kvart C, Lord P. Left atrial to
aortic root indices using two-dimensional and M-mode
echocardiography in Cavalier King Charles Spaniels with
and without left atrial enlargement. Vet Radiol Ultrasound
2002;43:568e75.
[14] Cornell CC, Kittleson MD, Della Torre P, Haggstrom J,
Lombard CW, Pedersen HD, Vollmar A, Wey A. Allometric
scaling of M-mode cardiac measurements in normal adult
dogs. J Vet Intern Med 2004;18:311e21.
[15] Buchanan JW, Bucheler J. Vertebral scale system to
measure canine heart size in radiographs. J Am Vet Med
Assoc 1995;206:194e9.
[16] Thomas WP, Gaber CE, Jacobs GJ, Kaplan PM,
Lombard CW, Moise NS, Moses BL. Recommendations for
standards in transthoracic two-dimensional echocardiog-
raphy in the dog and cat. Echocardiography committee of
the specialty of cardiology, American college of veterinary
internal medicine. J Vet Intern Med 1993;7:247e52.
[17] Cahill RJ, Pigeon K, Strong-Townsend MI, Drexel JP,
Clark GH, Buch JS. Analytical validation of a second-
generation immunoassay for the quantification of N-ter-
minal pro-B-type natriuretic peptide in canine blood. J Vet
Diagn Investig 2015;27:61e7.
[18] Ljungvall I, Hoglund K, Tidholm A, Olsen LH, Borgarelli M,
Venge P, Haggstrom J. Cardiac troponin I is associated with
severity of myxomatous mitral valve disease, age, and C-
reactive protein in dogs. J Vet Intern Med 2010;24:153e9.
[19] Fox PR, Oyama MA, Hezzell MJ, Rush JE, Nguyenba TP,
DeFrancesco TC, Lehmkuhl LB, Kellihan HB, Bulmer B,
Gordon SG, Cunningham SM, MacGregor J, Stepien RL,
Lefbom B, Adin D, Lamb K. Relationship of plasma N-ter-
minal pro-brain natriuretic peptide concentrations to
heart failure classification and cause of respiratory distress
in dogs using a 2nd generation ELISA assay. J Vet Intern
Med 2015;29:171e9.
[20] Porciello F, Rishniw M, Ljungvall I, Ferasin L, Haggstrom J,
Ohad DG. Sleeping and resting respiratory rates in dogs and
cats with medically-controlled left-sided congestive heart
failure. Vet J 2016;207:164e8.
[21] Borgarelli M, Savarino P, Crosara S, Santilli RA,
Chiavegato D, Poggi M, Bellino C, La Rosa G, Zanatta R,
Haggstrom J, Tarducci A. Survival characteristics and
prognostic variables of dogs with mitral regurgitation
attributable to myxomatous valve disease. J Vet Intern
Med 2008;22:120e8.
[22] Faber J, Fonseca LM. How sample size influences research
outcomes. Dental Press J Orthod 2014;19:27e9.
[23] Lewis T, Swift S, Woolliams JA, Blott S. Heritability of
premature mitral valve disease in Cavalier King Charles
spaniels. Vet J 2011;188:73e6.
[24] Serfass P, Chetboul V, Sampedrano CC, Nicolle A,
Benalloul T, Laforge H, Gau C, Hebert C, Pouchelon JL,
Tissier R. Retrospective study of 942 small-sized dogs:
prevalence of left apical systolic heart murmur and left-
sided heart failure, critical effects of breed and sex. J
Vet Cardiol 2006;8:11e8.
[25] Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Selected
echocardiographic variables change more rapidly in dogs
that die from myxomatous mitral valve disease. J Vet
Cardiol 2012;14:269e79.
[26] Lord P, Hansson K, Kvart C, Haggstrom J. Rate of change of
heart size before congestive heart failure in dogs with
mitral regurgitation. J Small Anim Pract 2010;51:210e8.
[27] Wolf J, Gerlach N, Weber K, Klima A, Wess G. Lowered N-
terminal pro-B-type natriuretic peptide levels in response
to treatment predict survival in dogs with symptomatic
mitral valve disease. J Vet Cardiol 2012;14:399e408.
[28] Fox PR, Oyama MA, Reynolds C, Rush JE, DeFrancesco TC,
Keene BW, Atkins CE, Macdonald KA, Schober KE,
Bonagura JD, Stepien RL, Kellihan HB, Nguyenba TP,
Lehmkuhl LB, Lefbom BK, Moise NS, Hogan DF. Utility of
plasma N-terminal pro-brain natriuretic peptide (NT-
52 M. Borgarelli et al.
proBNP) to distinguish between congestive heart failure
and non-cardiac causes of acute dyspnea in cats. J Vet
Cardiol 2009;11:S51e61.
[29] Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K,
Elliott J. The combined prognostic potential of serum high-
sensitivity cardiac troponin I and N-terminal pro-B-type
natriuretic peptide concentrations in dogs with degener-
ative mitral valve disease. J Vet Intern Med 2012;26:302e11.
[30] Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP,
Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL,
Lefbom BK, Meier CK, Oyama MA. Prediction of first onset
of congestive heart failure in dogs with degenerative
mitral valve disease: the PREDICT cohort study. J Vet
Cardiol 2012;14:193e202.
[31] Tarnow I, Olsen LH, Kvart C, Hoglund K, Moesgaard SG,
Kamstrup TS, Pedersen HD, Haggstrom J. Predictive value
of natriuretic peptides in dogs with mitral valve disease.
Vet J 2009;180:195e201.
[32] Falk T, Ljungvall I, Zois NE, Hoglund K, Olsen LH,
Pedersen HD, Haggstrom J. Cardiac troponin-I concen-
tration, myocardial arteriosclerosis, and fibrosis in dogs
with congestive heart failure because of myxomatous
mitral valve disease. J Vet Intern Med 2013;27:500e6.
[33] Controlled clinical evaluation of enalapril in dogs with
heart failure: results of the cooperative veterinary ena-
lapril study group. The COVE study group. J Vet Intern Med
1995;9:243e52.
[34] Group BS. The effect of benazepril on survival times and
clinical signs of dogs with congestive heart failure: results
of a multicenter, prospective, randomized, double-
blinded, placebo-controlled, long-term clinical trial. J
Vet Cardiol 1999;1:7e18.
[35] Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB,
Cohn JN. Effect of enalapril on survival in patients with
reduced left ventricular ejection fractions and congestive
heart failure. N Engl J Med 1991;325:293e302.
Available online at www.sciencedirect.com
ScienceDirect
Spironolactone and benazepril in preclinical mitral valve disease 53
